HilleVax Inc has a consensus price target of $11.67 based on the ratings of 6 analysts. The high is $30 issued by SVB Leerink on May 24, 2022. The low is $2 issued by Leerink Partners on July 9, 2024. The 3 most-recent analyst ratings were released by Leerink Partners, Stifel, and JP Morgan on July 9, 2024, July 9, 2024, and May 15, 2024, respectively. With an average price target of $9.67 between Leerink Partners, Stifel, and JP Morgan, there's an implied 422.52% upside for HilleVax Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/09/2024 | Buy Now | 8.11% | Leerink Partners | David Risinger | $28 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
07/09/2024 | Buy Now | 62.16% | Stifel | Stephen Willey | $34 → $3 | Downgrade | Buy → Hold | Get Alert |
07/09/2024 | Buy Now | — | HC Wainwright & Co. | Matthew Caufield | — | Downgrade | Buy → Neutral | Get Alert |
07/08/2024 | Buy Now | — | JP Morgan | Eric Joseph | — | Downgrade | Overweight → Neutral | Get Alert |
07/08/2024 | Buy Now | — | Guggenheim | Seamus Fernandez | — | Downgrade | Buy → Neutral | Get Alert |
05/15/2024 | Buy Now | 1197.3% | JP Morgan | Eric Joseph | $21 → $24 | Maintains | Overweight | Get Alert |
05/10/2024 | Buy Now | 1413.51% | HC Wainwright & Co. | Matthew Caufield | → $28 | Reiterates | Buy → Buy | Get Alert |
03/21/2024 | Buy Now | 1413.51% | HC Wainwright & Co. | Matthew Caufield | → $28 | Reiterates | Buy → Buy | Get Alert |
12/13/2023 | Buy Now | 1413.51% | HC Wainwright & Co. | Matthew Caufield | → $28 | Initiates | → Buy | Get Alert |
11/15/2023 | Buy Now | 1737.84% | Guggenheim | Seamus Fernandez | $38 → $34 | Maintains | Buy | Get Alert |
11/10/2023 | Buy Now | 1521.62% | Stifel | Stephen Willey | $35 → $30 | Maintains | Buy | Get Alert |
05/16/2023 | Buy Now | 1089.19% | JP Morgan | Eric Joseph | $23 → $22 | Maintains | Overweight | Get Alert |
05/24/2022 | Buy Now | 2062.16% | Guggenheim | Seamus Fernandez | → $40 | Initiates | → Buy | Get Alert |
05/24/2022 | Buy Now | 1521.62% | SVB Leerink | David Risinger | → $30 | Initiates | → Outperform | Get Alert |
05/24/2022 | Buy Now | 1197.3% | JP Morgan | Eric Joseph | → $24 | Initiates | → Overweight | Get Alert |
05/24/2022 | Buy Now | 1737.84% | Stifel | Stephen Willey | → $34 | Initiates | → Buy | Get Alert |
The latest price target for HilleVax (NASDAQ:HLVX) was reported by Leerink Partners on July 9, 2024. The analyst firm set a price target for $2.00 expecting HLVX to rise to within 12 months (a possible 8.11% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for HilleVax (NASDAQ:HLVX) was provided by Leerink Partners, and HilleVax downgraded their market perform rating.
There is no last upgrade for HilleVax
The last downgrade for HilleVax Inc happened on July 9, 2024 when Leerink Partners changed their price target from $28 to $2 for HilleVax Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HilleVax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HilleVax was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.
While ratings are subjective and will change, the latest HilleVax (HLVX) rating was a downgraded with a price target of $28.00 to $2.00. The current price HilleVax (HLVX) is trading at is $1.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.